ヒストンデアセチラーゼ阻害剤市場の競合分析

Competitor Analysis: HDAC Inhibitors

発行	La Merie Publishing
出版日	2009年07月	商品コード	96354
ページ情報	英文 42
価格	US$ 560 換算 ¥ 45,063 (税抜) PDF by E-mail (Single User License) US$ 1,120 換算 ¥ 90,126 (税抜) PDF by E-mail (Site License) US$ 1,680 換算 ¥ 135,189 (税抜) PDF by E-mail (Global Site License)

概要
原文目次
関連レポート

原文目次

Abstract

Product description

The present Competitive Intelligence Report about HDAC Inhibitors provides a competitor evaluation in the field of novel molecular entities inhibiting histone deacetylase for treatment of cancer and other diseases as of July 2009. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Histone deacetylase (HDAC) inhibitors are emerging as a new class of potential anticancer agents for the treatment of solid and hematological malignancies. HDAC inhibition causes acetylated nuclear histones to accumulate in both tumor and normal tissues, providing a surrogate marker for the biological activity of HDAC inhibitors in vivo. The effects of HDAC inhibitors on gene expression are highly selective, leading to transcriptional activation of certain genes such as the cyclin-dependent kinase inhibitor but repression of others. HDAC inhibition not only results in acetylation of histones but also transcription factors such as p53, GATA-1 and estrogen receptor-alpha.

HDAC inhibitors are potent antiproliferative agents with relatively little effect on normal tissues. The first generation of pan-HDAC inhibitor produced clinical benefit and the first representative of this class is already marketed for cutaneous T-cell lymphoma. The second generation inhibitors are rationally designed with improved specificity and are currently in broad clinical evaluation for a number of different cancer indications, alone and in combination.

Apart from oncology, HDAC inhibitors are also being evaluated in other indications, such as Huntington' s disease or Friedreich' s ataxia because transcriptional dysregulation has been shown to be a major pathology in Huntington' s Disease. There are CNS-penetrant, orally bioavailable HDAC inhibitors which are being pursued for use as a cognition enhancing agent in neurodegenerative diseases such as Alzheimer' s disease. Other indications under evaluation are fungal infections, psoriasis and inflammatory diseases.

The report includes a compilation of current active projects in research and development of HDAC inhibitors in oncology and other indications. In addition, the report lists company-specific R&D pipelines of HDAC inhibitors. Competitor projects are listed in a tabular format providing information on: